Compare Honest Company Inc (HNST) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honest Company Inc vs TG Therapeutics Inc — how do they compare? Honest Company Inc trades at $5.02 (market cap $542.86M), while TG Therapeutics Inc trades at $47.68 (market cap $7.58B). The key difference: TG Therapeutics Inc is far larger — about 14× Honest Company Inc's market cap, and Honest Company Inc is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HNST | TGTX | |
|---|---|---|
Market Cap | $542.86M | $7.58B |
Sector | Consumer Staples | Health |
52-Week High | $5.46 | $59.06 |
52-Week Low | $2.10 | $26.94 |
Enterprise Value | $446.47M | $7.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HNST trades at $5.03, down 3.45% today, with a mixed technical picture showing bullish moving averages but overbought RSI signals. The company reported Q2 2026 EPS of $0.04, beating estimates, though revenue declined to $342M in 2026. Strategic exits are improving profitability but impacting top-line growth, with net margins remaining negative at -3.56%.
The outlook is cautious; while operational improvements and record underlying profitability in Q2 2026 provide optimism, persistent revenue declines and negative margins pose risks. Analyst sentiment is mixed with 30% buy ratings, reflecting uncertainty around sustainable growth amid strategic shifts.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
